Citation for published version (APA): Douwes, J. M. (2017). Shaping the future of paediatric pulmonary arterial hypertension. [Groningen]: Rijksuniversiteit Groningen.
Introduction
Pulmonary arterial hypertension (PAH) is a disease characterized by pulmonary vascular remodelling, leading to severe elevation of right ventricular afterload, ultimately resulting in right ventricular (RV) failure and death. Despite emerging treatment options, PAH is a progressive disease and data on its diagnosis, treatment and outcome is limited, especially in children. 1 In PAH, treatment decisions are based on the assessment of disease severity and prognosis by the use of prognostic (surrogate-) parameters. 2, 3 There is a strong need for reliable prognostic parameters that can be used as clinical endpoints in order to guide the treatment of PAH. The currently used parameters are far from perfect, especially in young children with PAH. The World Health Organization functional class (WHOfunctional class) and 6-minute walk distance (6-MWD) are recognized as valuable prognostic parameters that are recommended to be used in goal-oriented treatment strategies in adult PAH-patients. [4] [5] [6] [7] In children, however, both parameters are often less reliable or not feasible because of young age and/or impaired development. 8 Haemodynamic parameters, such as pulmonary vascular resistance (PVR), and mean pulmonary arterial pressure (mPAP), are important objective measurements used to confirm the diagnosis of PAH. Furthermore, they may provide prognostic information. However, while invasive haemodynamic evaluation in children frequently requires general anaesthesia, the correlation of mPAP and PVRi with clinical status and survival is limited. 5, [9] [10] [11] [12] [13] [14] Elevated RV afterload leading to RV failure is the main determinant of mortality in PAH.
RV afterload consists of static components (PVR and mPAP) defining net forward flow, and pulsatile components defining flow and pressure oscillations. Pulsatile components include pulmonary arterial compliance (PAC), the ability of pulmonary arteries to accommodate oscillatory changes in volume, and pulmonary stroke volume (PSV), the amount of blood ejected in the pulmonary artery per cardiac cycle. The latter differs from RV stroke volume in the setting of intracardiac shunt or tricuspid regurgitation. Conventional haemodynamic parameters such as mPAP and PVRi only partially represent RV afterload, since they represent its static components and ignore its pulsatile components. 9, 15 In healthy subjects the pulsatile components contribute little to the RV afterload, due to the low resistance and high compliance of the pulmonary circulation. However in PAH their contribution to RV afterload becomes increasingly important due to arterial stiffening and increased reflection waves. 16, 17 PAC and PSV, both reflecting pulsatile components of the RV afterload, may therefore provide additional prognostic information in PAH.
Previous findings in adult PAH patients indicated that PAC and PSV may be valuable predictors for prognosis in adult PAH. [18] [19] [20] [21] In paediatric PAH, PAC has previously been shown to be associated with pulmonary vascular disease severity, however its prognostic value for mortality is not clear. [22] [23] [24] The purpose of this study was to determine the prognostic value of PSV and PAC in children with idiopathic/hereditary PAH (IPAH/HPAH) and PAH associated with congenital heart disease (PAH-CHD).
Methods
In the Netherlands, all paediatric PAH patients are referred to the University Medical Centre Groningen, the national referral centre within the Dutch National Network for Paediatric Pulmonary Hypertension. At the referral centre, the diagnosis of PAH is confirmed by heart catheterization, treatment strategies have evolved according to the 'ESC guidelines for the diagnosis and treatment of PAH' , and all patients are regularly seen at standardized follow-up visits. 2 We retrospectively reviewed the diagnostic heart catheterization data of all paediatric patients with IPAH/HPAH and PAH-CHD seen at the Dutch national referral centre from 1993 to 2010. PAH was defined as elevated mPAP ≥ 25 mmHg at rest, with a pulmonary capillary wedge pressure (mPCWP) ≤ 15 mmHg and elevated PVRi ≥ 3 Wood units · m2 measured during heart catheterization. Only patients who had a full baseline haemodynamic assessment by heart catheterization were included in the study. PAH-CHD patients were subdivided into three different groups, based on their circulatory physiology: 1) patients with an unrestricted pre-tricuspid shunt (atrial septal defects); 2) patients with an unrestricted post-tricuspid shunt ([atrio]ventricular septal defects, patent ductus arteriosus, or uncorrected univentricular heart with unobstructed pulmonary blood flow) and 3) patients with surgically corrected post-tricuspid shunt (without residual shunts) in whom PAH developed or persisted after shunt-closure.
A control group, which was age-and shunt-matched in order to rule out both age and circulatory physiology as possible confounding factors, was composed of patients with low pulmonary vascular resistance (PVRi<2.5 WU.m2), catheterized at the University Medical Centre Groningen. The control group included control patients with normal pulmonary circulation (patients with aortic stenosis) and shunt control patients with increased pulmonary blood flow index (Qpi/Qsi > 1.2) due to persistent ductus arteriosus, or atrial septal defects, with normal mPAP (<20 mmHg).
Our institutional human research committee approved the protocol for the Dutch national clinical patient registry and the use of its data for observational studies. Patients or their legal guardians provided informed consent. The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology.
Baseline evaluation
Baseline evaluation included WHO-functional class and diagnostic heart catheterization. Baseline haemodynamic measurements included mean right atrial pressure (mRAP), mPAP, pulmonary arterial pulse pressure (PP), mPCWP, PVR indexed for body surface area (PVRi), Qpi, pulmonary stroke volume index (PSVi) and pulmonary arterial compliance index (PACi). Qpi was determined by using Fick's method, based on estimated oxygen consumption (VO2). VO2 was estimated by using two methods: (i) for patients < 7 years of age VO2 = 1.39 × Height(cm) + 0.84 × Weight(kg) − 35.7 and (ii) for patients > 7 years of age by the tables of Lafarge and Miettinen. 25, 26 PVRi was determined by dividing the pulmonary arterial to venous pressure fall by Qpi. The PSVi was determined by dividing Qpi by the heart rate, and finally PACi was calculated by dividing PSVi by PP.
During heart catheterization, acute vasodilator challenge was performed by using inhaled nitric oxide (NO), or NO with 100% O2. In the case of sequential pulmonary vasodilator response tests with both conditions, the maximal response of each individual parameter was determined and used for analyses.
Statistical analyses
Data are presented as mean ± standard deviation, median (interquartile range) or number PACi, PSVi, mSAP and heart rate were split on their median for analyses with Kaplan-Meier curves. Subsequently, the correlation of continuous haemodynamic parameters and clinical parameters (WHO-class, diagnosis, shunt, age, therapy) with survival was evaluated by using Cox regression. Backward multivariate Cox regression was used to identify the strongest haemodynamic predictors for survival. In multivariate analyses the haemodynamic predictors were corrected for clinical parameters that were associated with survival in univariate analyses. All variables met the proportionality assumptions and there were no statistical interactions between variables that were combined in multivariable analyses.
Results

Patient characteristics
Fifty-two paediatric PAH patients (31 female, 21 male) and 17 control patients (6 female and 11 male) were included in this study. There were 32 IPAH/HPAH and 20 PAH-CHD patients (15 with post-tricuspid shunt, 1 with pre-tricuspid shunt and 4 with corrected shunt). Median age of the PAH patients was 7.1 years. The distribution of gender, age and shunt types did not differ between the PAH patients and the control group (Table 1) .
Patients were treated according to the evolving guidelines for diagnosis and treatment of pulmonary hypertension. 2 Nine patients did not receive PAH-targeted therapy because they were diagnosed and died in the era in which PAH-targeted therapy (endothelin receptor antagonist, PDE5-inhibitor or prostacyclin derivate) was not yet available in the Netherlands.
There were 23 patients on mono, and 20 patients on combination (dual or triple) PAHtargeted therapy.
Haemodynamics
The PAH patients had severe PAH with elevated mPAP and PVRi ( Table 2 ). In contrast, control subjects without a pulmonary to systemic shunt had normal mPAP, PVRi and Qpi. Control subjects with a pre-or post-tricuspid shunt had increased Qpi (median 6.9 L/min/m2) due to left to right shunting, accompanied by a low PVRi (range 0.5-1.1 WU.m2) and normal mPAP (range 10-17 mmHg). The mSAP of the control patients was comparable to the PAH patients, reflecting a successful patient matching procedure. The PSVi and PACi were both significantly decreased in the PAH patients compared to the controls. Except for the aorta saturation, there were no significant differences in baseline haemodynamics between the IPAH/HPAH and PAH-CHD patients. Both PSVi and PACi were lower in patients with higher WHO-functional class ( Figure 1 ). 41 (79%) PAH patients were tested for acute pulmonary vasodilator response. The mPAP, mPAP/mSAP and PVRi significantly decreased during acute vasodilator response (Table 3) , whereas mean pulmonary arterial pulse pressure did not significantly change. Both PSVi and PACi increased significantly during acute vasodilator response testing. 
Survival
The (Figure 2 ). Kaplan-Meier curves showed that a higher PSVi and a higher PACi were associated with better survival ( Figure 3A ). Furthermore, higher mSAP and lower heart rate were associated with improved survival ( Figure 3B ). The associations of PACi, PSVi, mSAP and heart rate with survival were not explained by differences in distribution of diagnosis, patients with HPAH or patients treated with prostacyclin derivate, between the percentile groups. Furthermore, there was no indication that the strength of these associations differed between the diagnosis subgroups.
In univariate Cox regression analyses higher PSVi, higher PACi, lower mPAP/mSAP, lower heart rate (during general anaesthesia) and higher mSAP were associated with better survival ( compared to patients for whom PAH-targeted therapy was not yet available. Therefore, subsequently, haemodynamic variables that were demonstrated to have an association with survival were corrected for WHO-functional class and PAH-targeted therapy in multivariate Cox regression analyses. These analyses showed that higher PSVi, higher PACi, lower heart rate, lower mPAP/mSAP and higher mSAP were associated with improved survival independent from WHO-functional class and PAH-targeted therapy ( Table 4 ). Younger patients tended to have worse survival compared to older patients. In order to adjust the survival analysis for the effect of age on mSAP and heart rate, the multivariate analyses were additionally corrected for age (Table 4 ). After correction for age, the point estimates of the associations remained the same, indicating that the associations were independent from age.
Two of the IPAH/HPAH patients (6.3%) showed acute vasodilator response according to the response criteria of the ESC guidelines. 2 Both patients survived during the study period and with that, responders tended to have improved survival compared to non-responders. However, individual haemodynamic variables during acute pulmonary vasodilator response testing did not provide additional information to the prognostic value of their baseline values.
Discussion
Despite the introduction of PAH-targeted therapy, paediatric PAH is still a severe disease with a detrimental prognosis, illustrated by reported survival rates in the current era. 11, 13 Conventional haemodynamic parameters represent only the static part of RV afterload and provide limited prognostic information. This study shows that pulsatile components of RV afterload provide important additional prognostic information.
The predictive value of PACi and PSVi for survival can be explained by their increasingly important role in pulsatile flow and RV afterload in PAH. 16 High compliant pulmonary arteries can reduce pulmonary arterial pressures and flow velocities, thereby delaying reflecting pressure waves. Reduced compliance leads to higher pressures, higher flow rate and early reflection waves, thereby increasing RV workload, which ultimately results in RV failure. Therefore in PAH, PACi reflects an important part of the RV afterload.
Since PACi and PVRi determine the ability of the pulmonary arteries to accommodate blood flow, a reduced PACi and increased PVRi leads to reduced PSVi. Increased RV afterload and the accompanying increased RV work load and hypertrophy in PAH, may eventually decrease PSVi even further. 27 One could question whether the association between PSVi and survival is driven by RV function or by progression of the pulmonary vascular disease. This is a complex Patients at risk  27  23  23  21  17  13  11  9  25  17  15  12  9  6  6  4   Patients at risk  26  24  23  21  15  10  9  7  26  16  15  12  11  9 issue, especially in a patient group with heterogeneous complex congenital heart diseases.
The current data show that the association of PSVi with outcome was found not only in IPAH/ HPAH, but also in PAH-CHD patients with a shunt at post-tricuspid level. In the latter patient group, PSVi is not synonymous to RV stroke volume due to right to left shunting and thus PSVi does not simply reflect RV function. In patients with intracardiac shunts, PSVi was associated with survival. Furthermore, there was no indication that the strength of the found associations with survival in PAH-CHD patients differed from that in iPAH/HPAH patients.
These findings support the notion that PSVi seems to represent a function of pulmonary vascular disease rather than of RV function.
PACi and PSVi both reflect disease severity in paediatric PAH. They are likely to decrease during disease progression of PAH and are candidate-parameters to assess disease severity and treatment effects. PSVi may more fully represent the progression of the vascular disease than PACi, since PSVi is determined by the RV afterload as a whole, including vascular resistance, arterial compliance and reflection waves, whereas PACi predominantly represents pulmonary arterial compliance. This may explain why our analyses indicates that PSVi is the stronger prognostic parameter in paediatric PAH compared to PACi.
Higher PACi was associated with improved survival independent from WHO-functional class and therapy, which is in congruence with previous reports in adult PAH. 18, 19 Sajan et al. 28 showed that in children with PAH, worse survival was predicted by either a higher or a lower than average PACi. In contrast, in the present study, the association between PACi and survival showed to be more linear. The reason for this disparity may lay in the difference in the composition of the study groups. Sajan et al. 28 included a large group of PAH-CHD patients with high PACi and it was unclear whether these patients all had advanced, irreversible PAH, whereas in the current study, all PAH-CHD patients had advanced irreversible PAH.
Higher PSVi was associated with improved survival in our study. RV stroke volume measured by pulmonary arterial MRI or by Fick's method has previously been shown to be a valuable prognostic factor in adult IPAH/HPAH. 20 In earlier reports cardiac index has been shown to be a prognostic parameter in iPAH. However, PSVi showed to be a stronger predictor of survival in both paediatric and adult PAH. 4, 13, 20 This can be explained by the fact that a decreased PSVi can be compensated by an increased heart rate, thereby maintaining cardiac output. The latter will affect the association of cardiac index with survival. 20 This notion is supported by the association of higher heart rate with decreased survival as found in the current study.
The investigated patient cohort included patients for whom advanced PAH therapy was not yet available. Evolving treatment strategies may influence outcome and survival analyses.
The analyses were corrected for this potentially confounding effect of treatment and the prognostic value of PACi and PSVi showed to be independent from treatment. This indicates that these associations were not affected by the evolving treatment strategies.
In this study the conventional, static parameters mPAP and PVRi were not associated with survival. PVRi and mPAP are important objective parameters in the confirmation of the diagnosis and assessment of disease severity in PAH. Although reports on the prognostic value of mPAP and PVRi in PAH are inconsistent, several studies in paediatric PAH have shown a lack of significant prognostic value of mPAP and/or PVRi in these patients. In paediatric PAH, PACi and PSVi appeared to be stronger predictors of survival compared to mPAP and PVRi. Therefore, in the clinical situation PACi and PSVi can provide prognostic information additional to conventional haemodynamic measurements, potentially improving goal-oriented treatment strategies.
In addition to PACi and PSVi, lower mPAP/mSAP, lower heart rate, and higher mSAP were associated with improved survival in our study. The association of mPAP/mSAP with survival is in congruence with previous reports, showing that high mPAP/mSAP is associated with poorer outcome in paediatric PAH. 13, 29 Since the associations of PACi and PSVi with survival were more stable in multivariate analysis than that of mSAP, mPAP/mSAP and heart rate, these pulsatile parameters seem to have a stronger prognostic value.
Heart rate and mSAP are affected by children's age, which by itself is associated with outcome in paediatric PAH. 12 Therefore age may partially explain their association with survival. In this study, the point estimates of the survival analyses remained numerically the same when corrected for age. Therefore the associations of heart rate, PACi, PSVi, mSAP and mPAP/mSAP with survival appear age independent.
The association of heart rate with survival, previously reported in adult PAH, may provide important clinical advantages. 30, 31 Heart rate is a non-invasive, easily obtainable parameter suitable for multiple follow-up measurements in paediatric PAH. Therefore heart rate may potentially be a valuable parameter to assist in guiding therapy in paediatric PAH.
Heart rate may both determine and respond to stroke volume of the RV, LV or both combined and with that it is strongly related with PSVi. Despite this intimate relation, both parameters appeared independent predictors of survival in this study. Therefore both parameters may have complementary value in guiding treatment.
Study limitations
Our analyses were limited by the relatively small number of patients. Nevertheless, we found strong correlations between survival and the pulsatile haemodynamic variables. In paediatric pulmonary hypertension, a very rare disease, patient numbers and data regarding survival and prognostic parameters are extremely limited. Therefore this study contributes largely to the currently available data.
Furthermore, no paired case-control matching could be performed due to the low number of available control patients. Congenital heart defects associated with systemic to pulmonary shunts and low PVRi are currently corrected at an early age before PVRi rises, leaving virtually no older patients with an important shunt and low PVR. Therefore a frequency matching approach was applied.
Conclusions
In conclusion, parameters of the pulsatile pulmonary circulation, such as PACi and PSVi, are associated with disease severity and predict survival in paediatric PAH, independent from conventional clinical prognostic parameters, such as PVRi. Therefore these parameters can be of complementary value to more conventional haemodynamic parameters in assessing disease severity, predicting survival and guiding treatment in paediatric PAH.
